In a 117-patient cohort, 35% waited over 60 days for neoadjuvant chemotherapy, most often because of added workup, second opinions or comorbidities.
News|Articles|March 4, 2026
Top ASCO GU 2026 Takeaways for Nurses and APPs
Author(s)Oncology Nursing News Staff
Explore safety and efficacy findings from KEYNOTE-B15/EV-304, LITESPARK-011, and more from the ASCO Genitourinary Cancers Symposium.
Advertisement
Advertisement
The 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium featured several high-impact studies detailing therapeutic advancements and patient-reported outcomes (PROs) across bladder, renal, and prostate cancers. For oncology nurses and advanced practice providers (APPs), these findings provide essential data on new treatment combinations, evolving safety profiles, and the long-term impact of therapy on patient quality of life (QOL).
Related to this article
Suzanne E. Barron, CRNP, explains how education, premedication, and pharmacy coordination streamline intravesical gene therapy treatment days.
Perioperative durvalumab with enfortumab vedotin given only before cystectomy cut the risk of an EFS event by 49% in the phase 3 VOLGA trial.
At the 10th Annual School of Nursing Oncology, faculty said nurses need fast, disease-specific updates to educate patients and manage novel therapies.
An ONS review presented at EONS19 outlines 7 system-level employer strategies to curb oncology nurse burnout and improve retention.
A Columbia nurse scientist shares her takeaways from the 2026 ASCO Quality Care Symposium, from geriatric assessment to care across the age span.
Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.
Among 90 patients with ES-SCLC, all CRS in the outpatient cohort was grade 1, and no patient in any care model was readmitted.
Advertisement
Advertisement